BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Victory Pharma, Inc. Announces US$45 Million Equity Financing


3/9/2009 7:16:45 AM

SAN DIEGO, March 9 /PRNewswire/ -- Victory Pharma, Inc. ("Victory" or "the Company"), a privately held specialty pharmaceutical company, today announced that it has closed on a US$45 million equity financing facility led by Essex Woodlands Health Ventures ("Essex"). Ampersand Ventures, an existing investor, also participated in the financing. Proceeds will be used to support future growth initiatives, including product acquisitions. As part of the transaction, Victory announced that Scott Barry, Essex Partner, has joined its Board of Directors.

"We are delighted to have Essex as an investor in Victory," President and CEO Matt Heck stated. "Their experience in building successful specialty pharmaceutical companies, significant fund size and reputation as a high quality, health care investor serve to further position Victory for its next phase of growth." Mr. Heck continued, "Importantly, in the course of the financing process, we found there is a good cultural fit between the Company and Essex, which was also very important to us."

Mr. Barry remarked, "Essex is excited to invest in such an experienced and successful management team which has demonstrated an ability to execute commercially with the Company's lead product NAPRELAN® and at prior companies. Victory is a rapidly growing, profitable business that we see as an excellent growth equity platform upon which to build a substantial specialty pharmaceutical company."

Cowen and Company, LLC acted as exclusive placement agent for the transaction.

About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA that is focused on acquiring, developing and marketing products to treat pain and related conditions. Victory markets its lead product, NAPRELAN (naproxen sodium) Controlled-Release Tablets and other pain products to pain management specialists, rheumatologists, orthopedic surgeons and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common, opiate-induced side effects. Further information regarding Victory Pharma is available at www.victorypharma.com.

NAPRELAN® is a trademark of Elan Corporation, plc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES